August 11th 2025
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.
New Data on Esketamine Nasal Spray as Treatment for Adolescents Contemplating Suicide
December 12th 2023These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.
Read More
“Terminal Anorexia”: An Invalid Construct That Does Not Justify Medical Aid in Dying
Does anorexia nervosa constitute an illness worthy of physician-assisted suicide? These authors think not.
Read More